Differentiation between Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura: A comparison of key laboratory findings between 2010 and 2021
DOI:
https://doi.org/10.33448/rsd-v13i12.47900Keywords:
Hemolytic Uremic Syndrome; Thrombotic Thrombocytopenic Purpura; Microangiopathies; Biomarkers.Abstract
Objective: This article aims to analyze and compare the clinical and laboratory findings related to Thrombotic Microangiopathies (TMAs), specifically Hemolytic Uremic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP), to support diagnostic and therapeutic decisions. The study also explores critical biochemical and hematological markers to differentiate these diseases. Methodology: A systematic literature review was conducted using articles from PubMed, Scielo, and Google Scholar, focusing on studies published from 2010 to mid-2021, covering a ten-year period. The review included research on clinical presentations, laboratory findings, and the molecular mechanisms underlying HUS and TTP. Results: The analysis revealed significant overlaps in clinical manifestations, such as anemia, thrombocytopenia, and renal dysfunction, but distinct differences in their pathophysiologies. HUS is associated with complement system dysfunction and Shiga toxin-mediated damage, while TTP is linked to ADAMTS13 enzyme deficiency. Laboratory markers such as lactate dehydrogenase, bilirubin, and platelet count were identified as crucial for differentiating the two conditions. Unique Contribution to Theory, Policy, and Practice: Underscoring the critical clinical and laboratory distinctions between HUS and TTP, this study provides a comprehensive framework for achieving precise diagnoses and developing individualized treatment strategies. Enhancing diagnostic accuracy is paramount to mitigating treatment delays, minimizing complications, and improving patient outcomes. Moreover, this review highlights the imperative need for standardizing diagnostic protocols for TMAs and advocates for further research to address existing knowledge gaps in this field.
References
Bayer, G., von Tokarski, F., Thoreau, B., Bauvois, A., Barbet, C., Cloarec, S., ... & Halimi, J. M. (2019). Etiology and outcomes of thrombotic microangiopathies. Clinical Journal of the American Society of Nephrology, 14(4), 557-566.
Caires, T. A. (2012). Fisiopatologia e diagnóstico da síndrome hemolítica urêmica. Academia de Ciência e Tecnologia.; 1(6), 10-11.
Drumond, J. P. N., Abou-Arabi, R. M., Figueiredo, R. P., Mourão, V. N., Aiziro, J. B., Caly, D. N., & Cortez, A. J. P. (2018). Thrombotic thrombocytopenic purpura: a case report. Jornal Brasileiro de Patologia e Medicina Laboratorial, 54(4), 255-259.
Farias, J. S. D. H., Cunha, J. P. P. D., Lagana, C. C. C., Gallucci, M. C., Chula, D. C., Soares, M. F., & Nascimento, M. M. (2016). Um caso de recuperação da função renal na síndrome hemolítico-urêmica tratada com eculizumab. Jornal Brasileiro de Nefrologia, 38(1), 137-141.
Gomes, I. S., & Caminha, I. D. O. (2014). Guide to systematic review of studies: an option for the methodology of Human Movement Sciences. Movimento-Porto Alegre, 20(1), 395-411.
Hansen, D. L., Nilsson, A. C., & Frederiksen, H. (2021). Thrombotic thrombocytopenic purpura. Ugeskrift for Laeger, 183(42), V03210230-V03210230.
Java, A. (2024). Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy. Hematology, 2024(1), 200-205.
Kavanagh, D., Raman, S., & Sheerin, N. S. (2014). Management of hemolytic uremic syndrome. F1000Prime Reports, 6.
Leisring, J., Brodsky, S. V., & Parikh, S. V. (2024). Clinical evaluation and management of thrombotic microangiopathy. Arthritis & Rheumatology, 76(2), 153-165.
Martelli, A. (2010). Síntese e metabolismo da bilirrubina e fisiopatologia da hiperbilirrubinemia associados à Síndrome de Gilbert: revisão de literatura. Rev Med Minas Gerais, 22(2), 216-220.
Menegazzo, A. B. B. R. (2014). Determinação do valor da heptoglobina sérica para diagnóstico de hemólise na síndrome HELLP.
Nieto-Rios, J. F., Zuluaga-Quintero, M., Valencia-Maturana, J. C., Bello-Marquez, D. C., Aristizabal-Alzate, A., Zuluaga-Valencia, G. A., ... & Arias, L. F. (2020). Síndrome hemolítico-urêmica causada por Escherichia coli produtora de toxina Shiga em um relato de caso de receptor de transplante renal. Brazilian Journal of Nephrology, 43, 591-596.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica .[free e-book]. Santa Maria: Núcleo de Tecnologia Educacional da Universidade Federal de Santa Maria.
Pérez-Cruz, F. G., Villa-Díaz, P., Pintado-Delgado, M. C., Fernández_Rodríguez, M. L., Blasco-Martínez, A., & Pérez-Fernández, M. (2017). Hemolytic uremic syndrome in adults: A case report. World Journal of Critical Care Medicine, 6(2), 135.
Pessegueiro, P., & Pires, C. (2005). Síndrome hemolítico urémico/púrpura trombocitopênica trombótica. Medicina Interna, 12(2), 102-116.
Polito, M. G., & Kirsztajn, G. M. (2010). Microangiopatias trombóticas: púrpura trombocitopênica trombótica e síndrome hemolítico-urêmica. Brazilian Journal of Nephrology, 32, 303-315.
Programa Nacional de Controle de Qualidade - CNPQ. (2019) Valores críticos de exames laboratoriais que necessitam de imediata tomada de decisão, em atendimento a RDC 302:2005 da ANVISA. http://pncq.org.br/uploads/2019/Valores%20cr%a1ticos%20no%20laborat%a2rio%20cl%a1nico_nov2019.pdf.
Reis, S., Ramos, D., Cordinhã, C., & Gomes, C. (2019). Desafios Diagnósticos e Terapêuticos na Síndrome Hemolítica Urémica Atípica: A Propósito de Um Caso Clínico. Acta Médica Portuguesa, 32(10), 673-675.
Schapkaitz, E., & Schickerling, T. M. (2018). The diagnostic challenge of acquired thrombotic thrombocytopenic Purpura in children: case report and review of the literature. Laboratory Medicine, 49(3), 268-271.
Tonaco, L. C., Rios, D. R., Vieira, L. M., Carvalho, M. D. G., & Dusse, L. (2010). Púrpura trombocitopênica trombótica: o papel do fator von Willebrand e da ADAMTS13. Revista Brasileira de Hematologia e Hemoterapia, 32, 155-161.
Vaisbich, M. H. (2014). Síndrome hemolítico-Urêmica na infância. Brazilian Journal of Nephrology, 36, 208-220.
Vaisbich, M. H., Henriques, L. D. S., Watanabe, A., Pereira, L. M., Metran, C. C., Malheiros, D. A., ... & Schvartsman, B. G. S. (2013). Uso do eculizumab na síndrome hemolítica urêmica atípica: relato de caso e revisão da literatura. Brazilian Journal of Nephrology, 35, 237-241.
Van Balen, T., Schreuder, M. F., de Jong, H., & van de Kar, N. C. (2014). Refractory thrombotic thrombocytopenic purpura in a 16‐year‐old girl: successful treatment with bortezomib. European Journal of Haematology, 92(1), 80-82.
Wang, X., Zhang, S., Li, L., Hua, J., Zhu, L., Li, L., & Zhang, G. (2018). Ticagrelor-induced thrombotic thrombocytopenic purpura: a case report and review of the literature. Medicine, 97(26), e11206.
Yates, S., Matevosyan, K., Rutherford, C., Shen, Y. M., & Sarode, R. (2014). Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion, 54(8), 2064-2067.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Matheus Ventura Pereira; Emanoelle Gomes Pereira; Kevin Fernandes Carriolo de Melo; Gabriella Oliveira Alves Moreira de Carvalho; Michel Alexandre Villani Gantus; Fabio Pereira Mesquita-Santos; Fabio da Silva de Azevedo Fortes; Anderson Jack Franzen
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
